Fundraising FoxTelegraph Hill Partners — 2023 Investments
5 investments dated 2023 · listed companies and verified rows first · show all
Mosaic Biosciences is a biologics discovery company that advances biologic drug candidates from discovery through IND-enabling studies and clinical development, working with partners across multiple therapeutic modalities.
BiotechDeep TechBoulder, US
Marty (Martin) Stanton(Founder & former CEO)inEric Furfine(Chief Scientific Officer)inAlexei Kazantsev(Vice President Protein Design and Engineering)inTracey Mullen(Chief Strategy Officer)inScott Glaser(SVP, Biologics Discovery)inJean-Pierre Wery(Chief Executive Officer)in
Board seatJeanette WelshRob Capone· per SEC Form D
Co-investorsMorgenthaler
Panome Bio provides metabolomics, proteomics, and multi-omics integration workflows along with a computational platform that analyzes and integrates diverse biological data types.
AI & Machine LearningBiotechDeep TechHealthtechSaint Louis, US
Edward Weinstein(Executive Officer, Director)inTom Cohen(Executive Officer)in
BoardDavid Smoller(Director)inAlexander Herzick(Director)in
Board seatDeval LashkariRob Capone· per SEC Form D
Co-investorsBioGenerator VenturesCultivation Capital
GrayHawk Health provides in-home and virtual medical care combined with individual health coaching for high-risk, older community members, coordinating clinical, social, and behavioral health needs.
Digital HealthHealthtechWellness & FitnessWayne, US
Andrew Henderson II(Executive Officer, Director)inRaymond Falci(Director)Marc Watkins(Director)Rob Hart(Director)in
RevMedica develops smart surgical stapling and soft tissue management systems for minimally invasive and robotic procedures, designed to provide real-time intraoperative data and improve clinical decision-making for surgeons.
AI & Machine LearningHealthtechMedical DevicesMiddletown, US
Thomas Wenchell(Chief Executive Officer and Co-Founder)inC. Robert Satti(Director)
Co-investorsConnecticut Innovations
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Frontier Psychiatry
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.